We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Multi-Parametric MRI and PET Imaging Improve Accuracy of Prostate Cancer Biopsies

By MedImaging International staff writers
Posted on 25 Jul 2016
Print article
Image: The graphic shows Gleason 3+4 prostate cancer in T2-weighted (A) and diffusion-weighted (B) MRI images. Graphic (C) shows F-18-choline PET, and graphic (D) shows PET/MRI (D) (Photo courtesy of the University of Michigan).
Image: The graphic shows Gleason 3+4 prostate cancer in T2-weighted (A) and diffusion-weighted (B) MRI images. Graphic (C) shows F-18-choline PET, and graphic (D) shows PET/MRI (D) (Photo courtesy of the University of Michigan).
Researchers have demonstrated that a combination of PET and multi-parametric MR imaging can improve targeted prostate cancer biopsies.

The study was published in the July 2016 issue of The Journal of Nuclear Medicine and found that adding F-18-choline Positron Emission Tomography (PET) molecular imaging to multi-parametric Magnetic Resonance Imaging (mpMRI) improves the chance of recognizing significant prostate cancer during targeted trans-rectal prostate biopsies.

The study, part of an ongoing prospective clinical trial was carried out by researchers at the University of Michigan (UMS; Ann Arbor, MI, USA) and included 36 subjects of which 15 were eventually identified with significant prostate cancer. The researchers concluded that image registration using fusion PET imaging together with MRI real-time Trans-Rectal Ultrasound (TRUS) during targeted prostate biopsies was accurate and clinically feasible. The addition of F-18-choline PET, to the mpMRI procedure resulted in improved identification of significant prostate cancer.

Morand Piert, MD, radiology professor, Division of Nuclear Medicine, University of Michigan, said, "Our positive results suggest that in the future, PET/MRI may become a one-stop imaging test for men with suspected but undetected prostate cancer or for patients undergoing surveillance for known low-risk prostate cancer. Since prostate cancer is often multi-focal and presents with multiple lesions of varying risk, it is important to identify the lesions that harbor the greatest malignant potential. Accurate identification of clinically significant cancer and avoidance of clinically insignificant cancer is the centerpiece of modern prostate cancer diagnosis. The use of advanced imaging to inform placement of biopsy needles promises to greatly minimize the uncertainty associated with prostate cancer care."

Related Links:
University of Michigan


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Laptop Ultrasound Scanner
PL-3018
Digital Radiography Acquisition Software
VXvue with PureImpact
New
Computed Tomography (CT) Scanner
Aquilion Serve SP

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.